Ionis Pharmaceuticals Inc (IONS) Position Lowered by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC lessened its position in shares of Ionis Pharmaceuticals Inc (NASDAQ:IONS) by 50.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,590 shares of the company’s stock after selling 6,674 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Ionis Pharmaceuticals were worth $334,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of IONS. Hanseatic Management Services Inc. raised its stake in shares of Ionis Pharmaceuticals by 1.2% during the 2nd quarter. Hanseatic Management Services Inc. now owns 3,481 shares of the company’s stock worth $177,000 after acquiring an additional 41 shares in the last quarter. The Manufacturers Life Insurance Company raised its stake in shares of Ionis Pharmaceuticals by 9.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,744 shares of the company’s stock worth $190,000 after acquiring an additional 311 shares in the last quarter. WFG Advisors LP raised its stake in shares of Ionis Pharmaceuticals by 77.2% during the 2nd quarter. WFG Advisors LP now owns 3,800 shares of the company’s stock worth $193,000 after acquiring an additional 1,655 shares in the last quarter. CIBC Asset Management Inc bought a new position in shares of Ionis Pharmaceuticals during the 3rd quarter worth approximately $212,000. Finally, Cambridge Investment Research Advisors Inc. bought a new position in shares of Ionis Pharmaceuticals during the 2nd quarter worth approximately $222,000. Hedge funds and other institutional investors own 91.40% of the company’s stock.

Several research analysts recently commented on the stock. BidaskClub lowered shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, December 22nd. Zacks Investment Research lowered shares of Ionis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, November 9th. BMO Capital Markets upped their price target on shares of Ionis Pharmaceuticals from $64.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday, November 8th. Morgan Stanley upped their price target on shares of Ionis Pharmaceuticals from $45.00 to $49.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 8th. Finally, Needham & Company LLC restated a “buy” rating and set a $64.00 price target on shares of Ionis Pharmaceuticals in a research note on Tuesday, October 17th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $50.31.

Ionis Pharmaceuticals Inc (NASDAQ IONS) opened at $50.02 on Thursday. The stock has a market cap of $6,220.00, a P/E ratio of 357.29 and a beta of 2.86. The company has a debt-to-equity ratio of 1.50, a quick ratio of 6.21 and a current ratio of 6.25. Ionis Pharmaceuticals Inc has a 52 week low of $37.26 and a 52 week high of $65.51.

In other news, Chairman Stanley T. Crooke sold 16,500 shares of the company’s stock in a transaction on Friday, October 13th. The shares were sold at an average price of $59.46, for a total value of $981,090.00. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Richard S. Geary sold 8,268 shares of the company’s stock in a transaction on Friday, October 13th. The shares were sold at an average price of $60.00, for a total transaction of $496,080.00. The disclosure for this sale can be found here. Insiders sold a total of 94,549 shares of company stock worth $5,538,170 over the last ninety days. Insiders own 2.13% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.chaffeybreeze.com/2018/01/04/ionis-pharmaceuticals-inc-ions-position-lowered-by-cubist-systematic-strategies-llc.html.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply